logo
Nectar Hybrid Mattress Review: Dense Support Meets Comfortable Cushion

Nectar Hybrid Mattress Review: Dense Support Meets Comfortable Cushion

Forbesa day ago
Nectar is a popular online mattress and bedding brand that was among the early pioneers of the bed-in-a-box style. It's one of our best-loved at Forbes Vetted for a number of reasons, but most of all because it offers great values, including the Nectar Classic Hybrid Mattress. This model is the sturdier coil version of the flagship Nectar Classic; it has similar pressure-relieving features with better spinal support and temperature regulation. Along with a long-term tester, nine of our team members tested this hybrid to see how it performed for differing genders, preferred sleep postures, body types and pain points. In this Nectar Hybrid Mattress review, we detail how it scored in important categories like pressure relief, support, firmness, motion isolation and more.
The Nectar Classic Hybrid Mattress has a balanced firmness profile, good motion isolation and ample ... More pressure relief. ILLUSTRATION: FORBES / PHOTO: RETAILER
The Nectar Hybrid Classic Mattress is an optimal choice for those who enjoy a medium-firm memory foam feel with enhanced responsiveness and support. Below, we highlight the bed's strengths, the types of sleepers we think it's best for and its potential drawbacks. If you prefer a softer feel, you might want to also consider other models from Nectar, such as the Nectar Luxe Hybrid or Nectar Ultra .
Forbes Vetted
Forbes Vetted ratings are based on thorough evaluations by our editorial team to help you choose the best products with confidence.
Type: Hybrid | Brand firmness rating: Medium-firm (6.5) | Trial period: 365 nights | Warranty: Lifetime
Buy if: You're a back, stomach or combination sleeper
You're a side sleeper over 150 pounds
You co-sleep with a partner (good motion isolation and edge support)
You live with back pain
Skip if:
Nectar recently revamped its entire lineup of mattresses, giving the Classic Hybrid a new look and feel that the majority of our testers liked. Mattress updates writer Alex Garrett says it feels similar to the new Nectar Memory Foam model in that 'it's firm yet cushioning with a touch of sinkage.' She adds, 'The only thing I notice that's separating them is the hybrid version is a little bouncier.' Another tester says, 'I fell in love with the feel of this mattress right off the bat. It might be because I'm biased toward hybrid mattresses , but this is better than the one I have at home.' With the current retail price around $800 for a queen size, our editors and testers agree it's a premium value.
Although this model is the brand's entry-level hybrid mattress, don't expect minimal features. Here's a breakdown of the 12-inch Nectar Hybrid. Cover: It has a soft cover that's made from a blend of polyester and viscose, and it's woven with cooling polyethylene fibers to help draw body heat away.
It has a soft cover that's made from a blend of polyester and viscose, and it's woven with cooling polyethylene fibers to help draw body heat away. Comfort layer: Beneath the cover is a 1-inch layer of comforting memory foam that cushions your joints and curves.
Beneath the cover is a 1-inch layer of comforting memory foam that cushions your joints and curves. Transition layer: Sandwiched in the middle of the bed is two inches of what the brand calls 'responsive support foam,' which helps lift the spine and prevent the mattress from offering too much sinkage.
Sandwiched in the middle of the bed is two inches of what the brand calls 'responsive support foam,' which helps lift the spine and prevent the mattress from offering too much sinkage. Support layer: Next is a system of 8-inch pocketed coils that are reinforced along the perimeter for greater support and sturdiness.
Next is a system of 8-inch pocketed coils that are reinforced along the perimeter for greater support and sturdiness. Base layer: A 1-inch layer of dense foam acts as the foundation for the rest of the mattress' materials.
A look at the five layers that make up the Nectar Classic Hybrid Mattress. Illustration: Forbes / Photo: Retailer
Nectar rates the Classic Hybrid Mattress a 6.5 on the firmness scale, with 10 being the firmest and 1 being the softest. All of our testers agreed it falls in the medium-firm ballpark, with most rating it a 6.5 as well. (We found the last version of this mattress to be softer than advertised.)
'This mattress is a nice balance between firm, bouncy and contouring,' says one tester who weighs under 150 pounds. 'I like that the memory foam in the top helps to add some cushion. Plus, the springs help distribute weight more evenly and offer good support.' Another tester echoes this thought and says, 'This bed has a nice middle ground between cushiony and dense; it provides that contouring feel that I prefer with a medium-firm profile.'
Although we typically advise side sleepers to choose a soft to medium mattress rather than a medium-firm one, our team rated the Nectar Classic Hybrid an 8 out of 10 for side sleeping because of its contouring and cushiony feel. However, this bed shines most for back and stomach sleepers, which we rated an 8.5 out of 10 for each position. Nectar Classic Hybrid Mattress Features
Firmness and feel are factors mainly influenced by weight and preferred sleep posture, but other important features like pressure relief, temperature and motion transfer remain more constant. Here's what our testers thought after putting the Nectar Classic Hybrid through our mattress testing process . Pressure Relief
Your mattress should properly cradle your joints and relieve pressure along your spine, otherwise it's not doing your body (and sleep) any good. Stomach and back sleepers typically require the least amount of pressure relief, while side sleepers benefit from more since their shoulder and hip bear greater weight. Our testers rated the Nectar Classic Hybrid an 8 out of 10 for pressure relief overall, crediting its medium-firm profile for providing both cushion and support. 'The mattress doesn't fully conform to my body, but it still is very comfortable. There is no pressure buildup in my neck, shoulders or hips while side sleeping,' says one tester.
Our long-term tester who slept on it in her home for 3o nights agrees, and says, 'The mattress provides excellent pressure relief, particularly when I sleep on my side. It has enough give to allow my shoulders and hips to sink in comfortably.' Lightweight side sleepers, on the other hand, should consider a softer mattress that has more cushion and give. Cooling
Memory foam mattresses are known to retain heat, but the Nectar Hybrid is designed to help combat this claim. Garrett says, 'The mattress cover is noticeably cooling,' while another tester adds, 'The cover feels cool to the touch and my body heat isn't badly trapped after lying in a single position for a while.' The coils inside the Nectar Hybrid let air flow through more efficiently, and its cover is woven with cooling fibers to help absorb excess body heat.
The Nectar Classic Hybrid features cooling tech in the cover to help absorb body heat. BRIDGET CHAPMAN FOR FORBES
However, our long-term tester says, 'While it wasn't enough to cause overheating during the night, if I happened to wake up for other reasons, I needed to change positions to alleviate the heat buildup underneath my body.' She adds that she'd recommend the Nectar Classic Hybrid for those who don't have major temperature regulation issues. If you sleep hot, you may want to consider a cooling mattress instead. Motion Transfer
Even though its coils help make the Nectar Hybrid Mattress more responsive, it still offers good motion isolation that deadens movement from your co-sleeper (whether it's a human or your restless pet). Our testers rated this category an 8.5 out of 10 after performing a water glass test, which entails placing a glass on one side of the mattress and making movements around it to see how the water's impacted. 'The motion isolation is pretty impressive on this mattress,' says one tester. 'I went tossing and turning, but the water in the glass only moved about half an inch in the glass, and the actual glass itself did not budge.' Another agrees on its performance and says couples would give it high marks. Support
Support is an important metric for anyone shopping for a mattress, but especially heavyweight individuals over 250 pounds and back and stomach sleepers. According to the brand, a queen-size Nectar Classic Hybrid can support up to 1,000 pounds of evenly distributed weight. One tester weighing between 150 and 250 pounds says, 'I feel like it provides a lot of support while still conforming to my body shape.'
It also received high marks for stomach sleeping, which our testers rated an 8.5 out of 10. However, our long-term tester thinks heavyweight stomach sleepers should consider a different choice. 'It doesn't feel like it causes a big enough misalignment in my spine to create an issue, however, a heavier stomach sleeper might find it does.' We recommend stomach sleepers over 250 pounds check out our list of the best mattresses for heavy people instead.
The Nectar Classic Hybrid can support up to 1,000 pounds. Jamie Ueda For Forbes
Edge support, or perimeter strength, is also an important factor, especially for couples who have to share a full- or queen-size mattress or people who like to sleep or sit on the side of the bed. During testing, we found this bed's edge support stands out as one of its strongest features (9 out of 10), thanks to its reinforced coils. 'Its edge support is impressive; I really do not notice much of a difference between the edges and center in terms of support,' says a tester. Ease Of Movement
Some memory foam mattresses provide pushback or resistance when you switch positions because your body has to warm up the material before it softens and gives. The Nectar Classic Hybrid Mattress is different in that it offers good ease of movement and takes the struggle out of changing sleep postures or getting in and out of bed. As a result, our testers rated its ease of movement an 8.5 out of 10. Nectar Classic Hybrid Mattress Pricing
Nectar is owned and operated by parent company Resident Home, which also owns the comfortable and competitively priced DreamCloud mattresses. Nectar mattresses are known for their signature feel that is reminiscent of memory foam from popular competitors, but Nectar offers some of the best values and company policies in the industry. Shipping And Delivery
Nectar offers free standard delivery where your mattress ships compressed in a box within three to five business days from when you order and then arrives two to five business days after that. You can upgrade to a white glove delivery service for an additional $199, which covers in-person delivery and setup of two items and old mattress removal if you choose. Trial Period And Returns
Most standard mattress trials are 100 nights, but Nectar offers 365 nights. You can choose to return your mattress for a full refund within the trial window, but Nectar asks you to wait at least 30 days to initiate a return so your body settles to the profile and feel of your new bed. Warranty
Nectar offers what it calls a Forever Warranty, which is essentially a limited lifetime guarantee. It states that if you experience specific defects in construction, materials or quality, the company will replace your mattress free of charge within the first ten years of ownership. After ten years, Nectar will fully repair your mattress, although shipping fees apply. To maintain coverage, it's important to follow the warranty guidelines carefully to avoid voiding the policy. Other Mattresses From Nectar
Nectar currently offers four different mattress models that are all available in all-foam and hybrid constructions, including the Premier and Ultra below.
In the next tier above the Nectar Classic Hybrid is the Nectar Premier Hybrid Mattress, which provides a slightly softer feel and a more advanced cooling cover. We think it's better for back and side sleepers who prefer something more cushioned than the dense, medium-firm Nectar Classic.
The Nectar Ultra Memory Foam Mattress is one of the brand's most premium choices. It has a softer, marshmallowy feel and a tall 15-inch profile that makes for a luxe sleep experience. We think it's best for side sleepers or lightweight back sleepers because of its doughy profile.
There aren't many mattresses that can suit back, stomach and side sleepers all at once, but the Nectar Classic Hybrid Mattress hits the mark. Unless you're a side sleeper under 150 pounds, you should enjoy its balanced feel and firmness, which testers say is both dense and cushioned. Couples should also enjoy its highlight features including edge support and motion isolation, meaning the perimeter is sturdy enough for those who share a smaller mattress and it deadens motion so you aren't disturbed by your partner's movements.
However, strict side sleepers and others who prefer a softer mattress should consider something more pressure relieving for the hips and shoulders, like the Nectar Ultra, which also comes in a hybrid version. On the other hand, if you're looking for a more supportive or firmer option, check out the best mattresses for heavy people and best firm mattresses instead. Why Trust Forbes Vetted
Our team of editors and writers has extensive experience in the sleep space and a passion to help you find quality products that lead to better rest. We also put every mattress through the same testing process to eliminate outside factors that may interfere with results and maintain consistency. McKenzie Dillon, author of this article, is a mattress and sleep editor at Forbes Vetted who has been researching and writing about the topic of sleep for over six years. She has her sleep science coach certification and has tested over 100 different beds, and has tested many different models from the Nectar and DreamCloud brands.
Bridget Chapman is the senior mattress and sleep editor at Forbes Vetted and oversees the category with Dillon. She has tested over 200 different beds and is a tenured editor in the mattress space with a sleep science coach certification. How We Tested The Nectar Classic Hybrid Mattress
We tested the Nectar Classic Hybrid Mattress in two ways: through group sessions and long-term individual use. So far this year, our team's tested over 90 mattresses in group settings, focusing on metrics that are essential for identifying the most accommodating and comfortable choice. During our group testing, eight individuals—all varying in size, sleep posture and more—tested the Nectar Classic Hybrid alongside dozens of other top-rated models.
We also had a long-term tester sleep on the Nectar Classic Hybrid at home for a full month to understand how it performs in a regular, overnight setting.
Our testers evaluated key features including firmness, feel, support, pressure relief, temperature, motion isolation and more.
How Long Does A Nectar Hybrid Last?
Nectar offers a limited lifetime warranty, meaning it will replace any hybrid mattress that has manufacturing defects within the first ten years of ownership free of charge. After ten years, it will completely repair and re-cover the mattress if it has a defined defect and charge a shipping fee. That said, a hybrid mattress should generally last around ten to 12 years with proper care, and no mattress should be used forever.
Is A Nectar Hybrid Mattress Good For Back Pain?
The Nectar Classic Hybrid Mattress has a medium-firm profile that balances support with pressure relief and a hybrid construction with steel coils, which are both features that doctors and experts recommend if you live with back pain.
Is The Nectar Hybrid Mattress Good For Side Sleepers?
The Nectar Classic Hybrid Mattress is good for most side sleepers over 150 pounds, but lightweight side sleepers should consider a softer mattress with more cushion and pressure relief.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump Threatens 100% Semiconductor Tariff—Why Chip Stocks Are Still Rising
Trump Threatens 100% Semiconductor Tariff—Why Chip Stocks Are Still Rising

Yahoo

time22 minutes ago

  • Yahoo

Trump Threatens 100% Semiconductor Tariff—Why Chip Stocks Are Still Rising

Key Takeaways Chip stocks advanced Thursday after President Donald Trump said companies that commit to manufacturing in the U.S. will be exempt from 100% tariffs on imported semiconductors. Trump's announcement was light on details about how the tariffs and exemptions would work, but analysts expect clarity within the next week. Wall Street analysts were optimistic that the vast majority of chip designers and manufacturers would win exemptions from manufacturing commitments or by contracting with U.S.-based stocks rose on Thursday, the day after President Donald Trump said companies that manufacture in the U.S. or have committed to doing so will be exempt from 100% semiconductor tariffs. 'We'll be putting a tariff of approximately 100% on chips and semiconductors. But if you're building in the United States of America, there's no charge,' Trump said during a White House press conference Wednesday afternoon. The tariffs were disclosed alongside Apple (AAPL) CEO Tim Cook, who appeared with Trump to announce plans to invest $100 billion in U.S. manufacturing, on top of the $500 billion committed earlier this year. President Trump's off-the-cuff announcement was light on details. For example, it was unclear whether existing commitments to manufacture in America would be sufficient, or if the president wants chipmakers to make new investments to win an exemption. It also remains unclear whether the tariffs and exemptions apply to electronics that contain semiconductors, or just the chips themselves, according to Jefferies analysts. "We await full details likely in the next week or so before jumping to any conclusions, as it has always been a bad move to extrapolate too much from Trump's words or social media post[s]," said Angelo Zino, senior vice president and equity analyst at CFRA Research. Nonetheless, investors seemed to think Wednesday's announcement removed a significant overhang for semiconductor stocks. The PHLX Semiconductor Index (SOX) was up 1.2% in recent trading. AI chip giants Nvidia (NVDA) and Broadcom (AVGO) were recently both up about 0.5%, though down from their earlier highs, while competitor Advanced Micro Devices (AMD) jumped 5%. Contract chip manufacturer Taiwan Semiconductor Manufacturing Co. (TSM) also advanced 5%, and manufacturing equipment maker Applied Materials (AMAT) rose more than 2%. Which Chipmakers Will Be Affected? 'From a high level, the 100% headline number seems intimidating, but in practice we expect a much lower impact,' wrote Bank of America Securities analysts in a note on Wednesday. U.S.-based companies with domestic manufacturing capacity, such as Intel (INTC), Micron (MU), and Texas Instruments (TXN), should not be affected by the tariffs, according to Citigroup analysts. And fabless chip designers, including giants Nvidia, AMD, Broadcom, and Qualcomm (QCOM), should also be able to avoid the tariffs by contracting with major foundries like TSMC, Samsung, and GlobalFoundries (GFS), all of which have U.S. manufacturing facilities. "If Taiwan Semi does get a full exemption ... it would bode well for the broader tech semiconductor/hardware ecosystem and our positive stance on the space," Zino of CFRA said. Even European semiconductor companies without a U.S. presence are expected to be spared the 100% levy. The EU-U.S. trade deal announced late last month capped semiconductor tariffs at 15% and guaranteed zero-for-zero tariffs for semiconductor equipment makers like Netherlands-based ASML (ASML). European Commission spokesperson Olof Gill on Thursday reportedly said the Trump administration had guaranteed that the 15% cap established by the trade deal would not be overwritten by other tariffs. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Peloton Just Shocked Wall Street -- And It's Not About a New Bike
Peloton Just Shocked Wall Street -- And It's Not About a New Bike

Yahoo

time22 minutes ago

  • Yahoo

Peloton Just Shocked Wall Street -- And It's Not About a New Bike

Peloton (NASDAQ:PTON) shares jumped by nearly 12% at 8.53am in premarket after the company posted a surprise profit and rolled out a tighter cost-control strategy that could reshape its post-COVID narrative. CEO Peter Sternwho joined in January after a stint at Fordhas been aggressively reshaping the business to combat sluggish demand for its high-end bikes and treadmills. That effort appears to be gaining momentum. Q4 revenue came in at $606.9 million, beating analyst estimates of $579.8 million. Even more notably, earnings landed at 5 cents per share, ahead of the expected 6-cent loss. Warning! GuruFocus has detected 7 Warning Signs with PTON. Signs of operational progress are emerging across the board. Peloton plans to cut 6% of its global workforce, relocate select offices, and slash indirect costsmoves that could save $100 million over the next fiscal year. The company's focus on profitability is already showing up in the numbers: operating expenses dropped 20% year over year, and general and administrative costs were down 33%. Gross margin from connected fitness products improved by 900 basis points to 17.3%, helping drive a 96% increase in gross profit for the segment. These improvements suggest Stern's playbook may be starting to deliver. Looking ahead, Peloton expects fiscal 2026 revenue to land between $2.4 billion and $2.5 billionslightly ahead of the $2.41 billion Wall Street was modeling, according to LSEG. However, the company flagged a potential $65 million hit to free cash flow due to tariffs and said it plans to offset that through price adjustments. While the road back to growth may still have hurdles, investors may view this update as a meaningful step forward. The turnaround story isn't done, but it's no longer on pause. This article first appeared on GuruFocus. Sign in to access your portfolio

Could This Psychedelic Drug Stock Be a Top Buy for 2026?
Could This Psychedelic Drug Stock Be a Top Buy for 2026?

Yahoo

time22 minutes ago

  • Yahoo

Could This Psychedelic Drug Stock Be a Top Buy for 2026?

Amid a global mental health crisis, the demand for new and effective treatment options is on the rise, particularly in the realm of psychedelic-assisted therapies. Experts believe the psychedelic drug market will grow from $4.1 billion in 2025 to an impressive $7.8 billion by 2030, reflecting a steady compound annual growth rate (CAGR) of 13.7%. As the space gains traction, one small biotech company has caught some investors' attention: Mind Medicine (MNMD), also known as MindMed for short. In its most recent earnings update, MindMed reported solid progress with enrollment across three pivotal Phase 3 trials for its lead candidate, MM120, a refined version of recreational drug lysergide d-tartrate (LSD) currently being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD). More News from Barchart Supermicro's Earnings Selloff Explained: Should You Buy SMCI Stock Now? Amazon's $36M Bet on Quantum Computing: What Investors Need to Know AMD Stock Slips After Q2 Earnings, But Here's Why It's a Buying Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Topline data from these trials is expected in 2026, setting the stage for a potential commercial launch by 2028. And analysts are also beginning to take notice. Oppenheimer, for example, recently expressed optimism based on what it believes could be 'powerful' Phase 3 data next year. So, with clinical milestones approaching, would it be wise to buy the shares of this psychedelic drugmaker? About Mind Medicine Stock MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its most advanced program, MM120, is currently in Phase 3 trials for GAD. Another key candidate, MM402, an MDMA-related compound, is in Phase 1 trials and being studied for its potential to address core symptoms of autism spectrum disorder (ASD). With a pipeline focused on conditions that often lack effective long-term solutions, the company is aiming to bring a fresh approach to mental health treatment. Valued at roughly $747 million by market capitalization, shares of this psychedelic therapy-focused company are gaining traction as investors take note of its advancing clinical pipeline and growing role in mental health innovation. Over the past year, shares have risen 34%, and the rally has only intensified in 2025 with a year-to-date (YTD) gain of 41%. That easily tops the broader S&P 500 Index's ($SPX) 22% gain over the past year and its 8% rise so far this year. Most notably, MindMed has surged 49% in just the last three months, highlighting growing investor interest. A Look Inside Mind Medicine's Q2 Earnings MindMed's fiscal 2025 second-quarter earnings, released on July 31, painted a mixed picture as the company deepens its push into late-stage development. The pre-revenue biotech firm posted a loss of $0.50 per share, widening from a loss of $0.26 a year ago and missing Wall Street's forecast of a $0.38 loss per share. The shortfall was driven by a sharp increase in research and development expenses, which surged 103.5% year-over-year (YOY) to $29.8 million, primarily due to the advancement of the MM120 program. While the company is investing heavily in advancing the MM120 program, one area of concern is the limited insight into the treatment's long-term effectiveness. So far, Phase 2 data only tracks results up to 12 weeks, leaving questions about how durable the benefits may be over an extended period. That said, MindMed's financial position remains strong. As of June 30, the company reported $237.9 million in cash, cash equivalents, and investments, enough to support operations into 2027 and beyond the first topline readout from its Phase 3 MM120 ODT trial. Meanwhile, clinical progress continues to move forward. MindMed remains on schedule with enrollment across three pivotal Phase 3 trials — Voyage, Panorama, and Emerge — which are focused on MM120 ODT for the treatment of GAD and MDD. These studies are designed to assess the efficacy of MM120 ODT as a standalone treatment, without the need for psychotherapy. The company expects topline data from its Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half. What Do Analysts Think About Mind Medicine Stock While investors' reaction to the company's Q2 results was somewhat underwhelming, sentiment took a sharp positive turn on Aug. 4 when shares jumped nearly 11% following an upgrade from Oppenheimer. Analyst Jay Olson lifted the psychedelic drug developer to an 'Outperform' rating and set a 12- to 18-month price target of $25, citing the promising potential of its lead candidate, MM120. Olson highlighted MM120's 'unique clinical profile,' describing it as a pharmaceutical form of LSD that delivers a less intense but longer-lasting psychedelic experience compared to other approaches. The analyst also emphasized the drug's potential in treating neuropsychiatric conditions like GAD and MDD. Backing his optimism, Olson noted encouraging Phase 2 trial data for MM120 in GAD, which showed favorable remission rates as well as a favorable safety and tolerability profile over a 12-week period. In his view, MindMed remains undervalued and is strategically positioned ahead of its anticipated Phase 3 readout Overall, MNMD stock has earned a resounding vote of confidence on Wall Street, carrying a consensus rating of 'Strong Buy.' Of the 11 analysts covering the stock, a majority of 10 analysts recommend a "Strong Buy" while the remaining one gives a 'Moderate Buy' rating. The average analyst price target of $25 indicates significant upside potential of 157% from the current price levels. Final Thoughts While MindMed's journey comes with the usual biotech risks — especially given its pre-revenue status, rising R&D costs, and questions around the long-term durability of MM120's effects — the company's progress in late-stage trials, strong financial position, and growing confidence from Wall Street paint an encouraging picture. For investors comfortable with biotech volatility and looking to gain exposure to the emerging psychedelic therapy space, MindMed could be a promising buy ahead of its anticipated Phase 3 milestones in 2026. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store